Novo Nordisk's Price War and AI Gamble to Defend Market Crown

Novo Nordisk slashes U.S. drug prices up to 50% by 2027 and partners with OpenAI to counter Eli Lilly's competitive threat, as shares tumble over 20% this year.

Novo Nordisk is slashing prices and embracing artificial intelligence in a dual-pronged strategy to defend its dominance in the weight-loss drug market. The Danish pharmaceutical giant announced it will cut U.S. list prices for its blockbuster drugs Wegovy and Ozempic by up to 50% starting in January 2027, a radical move that sacrifices high margins for market share. This aggressive pricing shift comes as competitive pressure from rival Eli Lilly intensifies.

Recent clinical data has reshaped the competitive landscape. A head-to-head study showed Eli Lilly's rival therapy achieved an average weight loss of 25.5%, outperforming Novo Nordisk's 23% result. This performance gap has forced the company's hand. The new strategy will see a monthly supply in the U.S. priced at approximately $675.

Simultaneously, Novo Nordisk is undergoing a profound corporate transformation. After cutting roughly 7,800 jobs last year—about 10% of its workforce—the company is now hiring again under CEO Mike Doustdar. It has already brought on 1,400 new employees to bolster production and research for its core therapies. To accelerate drug discovery, the firm has sealed a strategic partnership with OpenAI, aiming to fully integrate the AI systems by the end of 2026. Financial terms of the deal were not disclosed.

The race for market supremacy is increasingly being fought with data. Eli Lilly is also leveraging OpenAI's services and collaborating with Nvidia, highlighting that competition will be decided by superior data analysis. Lilly further tightened the screws this month by securing U.S. approval for its new weight-loss pill, Foundayo.

Investors have reacted harshly to the mounting challenges. Novo Nordisk's share price has plummeted nearly 23% since the start of the year, currently trading at €34.44. This represents a decline of over 50% from its recent peak. The stock's Relative Strength Index (RSI) reading of 25 indicates it is deeply oversold.

Management is deploying a share buyback program to provide support. The ongoing initiative has a total volume of up to 15 billion Danish kroner, with the company having repurchased shares worth 3.8 billion kroner by early May. To meet the anticipated surge in demand from lower prices, Novo Nordisk is planning a record capital expenditure budget of 55 billion Danish kroner for 2026, primarily to expand production capacity.

All eyes are now on the company's first-quarter results, scheduled for release on May 6. This report will offer the first comprehensive look at performance under the new strategic direction. Management has already guided for a sales decline in 2026, with expectations ranging from a 5% to a 13% drop. Investors will be keen for details on how quickly increased sales volumes can offset the massive price cuts. Chart watchers note that if the share price fails to hold support around its annual low of €30, further selling pressure could emerge.